|
|
Article: Heart Choices; A cholesterol drug study suggests that consumers have been lured into overspending.
- Article from:
- The Washington Post
- Article date:
- February 2, 2008
|
Copyright informationThis material is published under license from the Washington Post. All inquiries regarding rights should be directed to the Washington Post. (Hide copyright information)
|
IT'S NO WONDER medical costs are skyrocketing: Companies such as
Merck and Schering-Plough have been brilliantly marketing a drug
that hasn't been shown to improve health.
The two manufacturers released the results of a cholesterol study
last month that compared Zocor, a generic cholesterol treatment,
with Vytorin, a drug that combines Zocor with another drug called
Zetia. Despite Vytorin's massive marketing campaign, the drug looks
to be no more effective at reducing artery plaque than Zocor alone,
even though Vytorin is three times as expensive as generic Zocor.
The study results have led to much confusion among patients.
Despite the rumors, Vytorin is not known to be dangerous; it's just ...
Related newspaper, magazine, and journal articles:
|